Search

Your search keyword '"Bloomfield, Marketa"' showing total 135 results

Search Constraints

Start Over You searched for: Author "Bloomfield, Marketa" Remove constraint Author: "Bloomfield, Marketa"
135 results on '"Bloomfield, Marketa"'

Search Results

1. Heterozygous BTNL8 variants in individuals with multisystem inflammatory syndrome in children (MIS-C).

2. Variants in IGLL1 cause a broad phenotype from agammaglobulinemia to transient hypogammaglobulinemia

4. Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

7. JAK inhibitor treatment for inborn errors of JAK/STAT signaling: An ESID/EBMT-IEWP retrospective study

8. Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity

10. Nationwide observational study of paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the Czech Republic

17. Unexpected relevant role of gene mosaicism in patients with primary immunodeficiency diseases

20. Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity

22. Activated Phosphoinositide 3-Kinase δ Syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity

23. Pathogenesis, immunology, and immune-targeted management of the multisystem inflammatory syndrome in children (MIS-C) or pediatric inflammatory multisystem syndrome (PIMS): EAACI Position Paper

25. Pathogenesis, immunology, and immune-targeted management of the multisystem inflammatory syndrome in children (MIS-C) or pediatric inflammatory multisystem syndrome (PIMS)

26. Inborn errors of OAS–RNase L in SARS-CoV-2–related multisystem inflammatory syndrome in children

27. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

29. EAACI statement on the pathogenesis, immunology, and immune-targeted management of the Multisystem Inflammatory Syndrome in Children (MIS-C) or Pediatric Inflammatory Multisystem Syndrome (PIMS).

30. Expanded population of lowdensity neutrophils in juvenile idiopathic arthritis.

33. B cells, BAFF and interferons in MIS-C

34. Risk Factors for Severe COVID-19 and Hospital Admission in Patients With Inborn Errors of Immunity - Results From a Multicenter Nationwide Study

35. The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodies

36. TLR8 / TLR7 dysregulation due to a novel TLR8 mutation causes severe autoimmune hemolytic anemia and autoinflammation in identical twins

37. Impact of JAK Inhibitors in Pediatric Patients with STAT1 Gain-of-Function (GOF) Mutations – 10 Children and Review of the Literature

38. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

39. X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19

40. Pathogenesis, immunology, and immune‐targeted management of the multisystem inflammatory syndrome in children (MIS‐C) or pediatric inflammatory multisystem syndrome (PIMS): EAACI Position Paper.

41. SARS-CoV-2-related MIS-C:A key to the viral and genetic causes of Kawasaki disease?

44. The prevalence, clinical relevance and origin of autoantibodies in patients with Common variable immunodeficiency on regular immunoglobulin replacement therapy – the results from a prospective observational study

49. Disharmonic Inflammatory Signatures in COVID-19: Augmented Neutrophils’ but Impaired Monocytes’ and Dendritic Cells’ Responsiveness

50. Complex Immunometabolic Profiling Reveals the Activation of Cellular Immunity and Biliary Lesions in Patients with Severe COVID-19

Catalog

Books, media, physical & digital resources